Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated